Lawsuit Alert: Investors in shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) should contact the Shareholders Foundation

An investor, who purchased shares of Pacira BioSciences, Inc. (NASDAQ: PCRX), filed a lawsuit over alleged violations of Federal Securities Laws by Pacira BioSciences, Inc. in connection with certain allegedly false and misleading statements.

Investors who purchased shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) have certain options and for certain investors are short and strict deadlines running. Deadline: March 14, 2025. NASDAQ: PCRX investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Tampa, FL based Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. On August 9, 2024, Pacira BioSciences, Inc announced the results of its lawsuit against eVenus for patent infringement. Pacira BioSciences, Inc disclosed that the court "found that the company's U.S. Patent No. 11,033,495 (the '495 patent) is not valid," and, thus, eVenus is not infringing on anything. Pacira's '495 patent is for Exparel, which is the main source of growth for the Company, encapsulating roughly 80% of its revenue. Analysts have noted that the invalidity of the '495 patent calls into question the validity of the Company's other patents, potentially resulting in more generic entrants into the market and increased litigation expenses moving forward.

Shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) declined from $31.67 per share on May 17, 2024, to as low as $11.16 per share on August 13, 2024.

The plaintiff claims that between August 2, 2023 to August 8, 2024, the defendants made false and/or misleading statements and/or failed to disclose that defendants created the false impression that Pacira had sufficient patent protections on Exparel, and as such, the ability to expand the marketing, production, and sales of Exparel, which Pacira stated was critical to its future growth and revenue, that Pacira knew that the '495 patent was not as protective as Pacira publicly touted because on June 6, 2023, the United States District Court for the District of New Jersey issued a ruling in eVenus Pharmaceutical Laboratories, Inc.'s favor regarding claims construction in another case filed by Pacira in a failed attempt to protect Exparel, and that therefore, when the '495 patent was invalidated in another case Pacira filed against eVenus, investors and analysts alike were shocked by the concerning news that Exparel, which accounts for approximately 80% of Pacira's revenue, did not have sufficient patent protection to prevent another company from producing a generic during the life of the patent.

Those who purchased shares of Pacira BioSciences, Inc. (NASDAQ: PCRX) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.